Positive Early Signs For Acumen’s Bid To Go Beyond Leqembi In Alzheimer’s
Drugs Targets Most Toxic Amyloid Form
Phase I data shows the oligomer-targeting antibody was safe and effective, and Acumen will now move ahead to a potentially pivotal Phase II/III study in Alzheimer’s disease.
